AKT1 and glioblastoma: Functional assay confirmed IGF2BP3 as a target of miR-129-1, while targeting of IGF2BP3 by miR-129-1 decreases the MAPK/ERK and PI3K/AKT cascade which leads to the postponement of G1-S transition in the cell cycle in glioblastoma cells [56].